Idiopathic Anaphylaxis—A Diagnostic and Therapeutic Dilemma

Julie K. Kim, David A. Khan

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Idiopathic anaphylaxis is a diagnosis of exclusion which falls in the spectrum of mast cell activation disorders. The role of bone marrow biopsy remains controversial, but in the appropriate clinical context, this diagnostic tool may be useful in ruling out a potential systemic mast cell process. There is no definitive treatment for idiopathic anaphylaxis, but omalizumab and rituximab show a promising role in prevention. At this time, data suggesting a role for these two monoclonal antibodies come from case reports but do not prove causation or efficacy of therapy. Clinical trials further investigating efficacy of these options are warranted.

Original languageEnglish (US)
Pages (from-to)183-192
Number of pages10
JournalCurrent Treatment Options in Allergy
Issue number3
StatePublished - Sep 2015


  • Bone marrow biopsy
  • Diagnosis
  • Idiopathic anaphylaxis
  • Mast cell activation
  • Omalizumab
  • Rituximab
  • Treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Medicine (miscellaneous)


Dive into the research topics of 'Idiopathic Anaphylaxis—A Diagnostic and Therapeutic Dilemma'. Together they form a unique fingerprint.

Cite this